Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Brenipatide (LY3537031) in Adults With IBS-D
jRCT2031260148Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing LY3537031 (Brenipatide) with Placebo (2 arms). Primary endpoint: Primary composite response. Started Apr 2026; status: recruiting.
02
Drugs
brenipatide
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on jRCT2031260148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260148.